Ondas Holdings Surges 8.04% on $340M Volume Ranks 324th in Market Activity as FDA Anticipation Drives Liquidity

. , ranking 324th in market activity. The biotech firm’s shares experienced heightened liquidity as investors reacted to strategic positioning ahead of potential FDA feedback on its lead asset. Analysts noted the move aligned with broader market rotation into small-cap innovation plays amid easing macroeconomic concerns.

Recent regulatory filings highlighted Ondas’ updated clinical trial timelines, with Phase II data expected by Q4 2025. , signaling renewed confidence in the company’s pipeline diversification strategy. , reflecting reduced bearish positioning ahead of upcoming catalysts.

, , . The approach involved daily rebalancing of top 500 U.S. stocks by volume, with intraday execution to mitigate overnight risk. , .